Juvenescence, a Tortola, British Virgin Islands-based life sciences company, closed its $100m Series B funding round.
This includes a total of $10 million from its founders and a further $10 million each from four cornerstone investors, including Grok Ventures, the investment company of Mike Cannon-Brookes (Atlassian cofounder), and Michael Spencer’s private investment company, IPGL.
This brings the total to $165M that Juvenescence has raised in 18 months.
The company will use the funds to progress many of its programs to their initial inflection points.
Founded by Jim Mellon, Dr. Greg Bailey and Dr. Declan Doogan, Juvenescence leverages expert drug developers and artificial intelligence experts to create therapeutics and technologies to treat diseases of aging and to increase human longevity.
The company creates, partners with or invests in new companies with longevity-related therapeutics, by in-licensing compounds from academia and industry, or forming joint ventures to develop therapeutics for longevity.